Chugai Pharmaceutical Co., Ltd. (CHGCF)
USD 43.95
(44.76%)
USD 43.95
(44.76%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 6.48 Billion JPY | 1606.98% |
| 2022 | -430 Million JPY | 12.24% |
| 2021 | -490 Million JPY | 13.12% |
| 2020 | -564 Million JPY | 12.29% |
| 2019 | -643 Million JPY | -884.15% |
| 2018 | 82 Million JPY | -60.39% |
| 2017 | 207 Million JPY | -59.41% |
| 2016 | 510 Million JPY | -15.56% |
| 2015 | 604 Million JPY | 226.49% |
| 2014 | 185 Million JPY | -5.13% |
| 2013 | 195 Million JPY | 0.0% |
| 2012 | - JPY | 0.0% |
| 2011 | - JPY | 0.0% |
| 2010 | - JPY | 0.0% |
| 2009 | - JPY | 0.0% |
| 2008 | - JPY | 0.0% |
| 2007 | - JPY | -100.0% |
| 2006 | 151 Million JPY | 0.0% |
| 2005 | - JPY | 0.0% |
| 2004 | - JPY | -100.0% |
| 2003 | 1 Billion JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - JPY | 0.0% |
| 2024 Q1 | - JPY | 0.0% |
| 2023 Q1 | - JPY | 100.0% |
| 2023 Q3 | - JPY | 0.0% |
| 2023 Q2 | - JPY | 0.0% |
| 2023 FY | 6.48 Billion JPY | 1606.98% |
| 2023 Q4 | 6.48 Billion JPY | 0.0% |
| 2022 Q3 | - JPY | 0.0% |
| 2022 Q4 | -430 Million JPY | 0.0% |
| 2022 Q2 | - JPY | 0.0% |
| 2022 Q1 | - JPY | -100.0% |
| 2022 FY | -430 Million JPY | 12.24% |
| 2021 FY | -490 Million JPY | 13.12% |
| 2021 Q1 | - JPY | -100.0% |
| 2021 Q2 | - JPY | 0.0% |
| 2021 Q3 | - JPY | 0.0% |
| 2021 Q4 | 9.49 Billion JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 Q1 | - JPY | -100.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 FY | -564 Million JPY | 12.29% |
| 2020 Q4 | 4.63 Billion JPY | 0.0% |
| 2019 Q1 | - JPY | -100.0% |
| 2019 FY | -643 Million JPY | -884.15% |
| 2019 Q2 | - JPY | 0.0% |
| 2019 Q4 | 5.48 Billion JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2018 Q3 | 114 Million JPY | -22.45% |
| 2018 Q4 | 82 Million JPY | -28.07% |
| 2018 Q1 | 180 Million JPY | -13.04% |
| 2018 FY | 82 Million JPY | -60.39% |
| 2018 Q2 | 147 Million JPY | -18.33% |
| 2017 Q4 | 207 Million JPY | -13.39% |
| 2017 Q2 | 271 Million JPY | -43.19% |
| 2017 Q1 | 477 Million JPY | -6.47% |
| 2017 FY | 207 Million JPY | -59.41% |
| 2017 Q3 | 239 Million JPY | -11.81% |
| 2016 Q4 | 510 Million JPY | -2.49% |
| 2016 FY | 510 Million JPY | -15.56% |
| 2016 Q1 | 575 Million JPY | -4.8% |
| 2016 Q3 | 523 Million JPY | -4.91% |
| 2016 Q2 | 550 Million JPY | -4.35% |
| 2015 Q4 | 604 Million JPY | -3.97% |
| 2015 Q3 | 629 Million JPY | 232.8% |
| 2015 Q2 | 189 Million JPY | 3.28% |
| 2015 FY | 604 Million JPY | 226.49% |
| 2015 Q1 | 183 Million JPY | -1.08% |
| 2014 FY | 185 Million JPY | -5.13% |
| 2014 Q1 | 186 Million JPY | -4.62% |
| 2014 Q4 | 185 Million JPY | 2.78% |
| 2014 Q3 | 180 Million JPY | 0.56% |
| 2014 Q2 | 179 Million JPY | -3.76% |
| 2013 Q3 | 203 Million JPY | -3.33% |
| 2013 Q4 | 195 Million JPY | -3.94% |
| 2013 Q2 | 210 Million JPY | -0.94% |
| 2013 FY | 195 Million JPY | 0.0% |
| 2013 Q1 | 212 Million JPY | -0.47% |
| 2012 FY | - JPY | 0.0% |
| 2012 Q1 | - JPY | -100.0% |
| 2012 Q2 | - JPY | 0.0% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q4 | 213 Million JPY | 0.0% |
| 2011 FY | - JPY | 0.0% |
| 2011 Q4 | 170 Million JPY | 0.0% |
| 2011 Q2 | - JPY | 0.0% |
| 2011 Q1 | - JPY | 0.0% |
| 2011 Q3 | - JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 FY | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 Q1 | - JPY | 0.0% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 Q3 | - JPY | 0.0% |
| 2009 Q2 | - JPY | 0.0% |
| 2009 Q1 | - JPY | 0.0% |
| 2009 FY | - JPY | 0.0% |
| 2008 FY | - JPY | 0.0% |
| 2007 FY | - JPY | -100.0% |
| 2006 FY | 151 Million JPY | 0.0% |
| 2005 FY | - JPY | 0.0% |
| 2004 FY | - JPY | -100.0% |
| 2003 FY | 1 Billion JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 70.985% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 83.029% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | -5952.794% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 67.655% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -33316.021% |